Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice

Trial Profile

Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Donepezil (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 29 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 07 Apr 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 18 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top